News
-
3P Innovation has announced the launch of a new version of its R500 Robotic Capsule and Device Filler which is scalable and capable of filling inhalers directly as well as filling capsules. According to 3P,… Read more . . .
-
Deepro nebulizer maker HCmed has announced that Vivo Capital’s PANDA Fund has become a strategic investor as of December 27, 2017, saying, “As a healthcare focused investment firm, Vivo will fully support HCmed’s strategic plan… Read more . . .
-
Inhaled drug developer Savara has announced the appointment of Peter Ginsberg as VP of Business Development. Ginsberg was most recently VP of Business Development at BioDelivery Sciences International and had previously held business development positions… Read more . . .
-
A Phase 3 trial of Liquidia Technologies’ LIQ861 treprostinil DPI for the treatment of pulmonary arterial hypertension (PAH) is underway, the company said. The study is expected to enroll a minimum of 100 PAH patients… Read more . . .
-
Egalet Corporation has terminated a co-promotion agreement with Septodont, the company said, and is now partnered with Valeant’s OraPharma division for co-promotion of Sprix ketorolac tromethamine nasal spray to US dentists and oral surgeons. Sprix… Read more . . .
-
Janssen Research & Development has published data from a Phase 2 study of its intranasal esketamine that demonstrate rapid improvement of symptoms in patients with treatment-resistant depression. The study was conducted from 2014-2015, and results… Read more . . .
-
By Lei Zhang, PhD, Deputy Director, Office of Research and Standards The FDA’s Center for Drug Evaluation and Research, Office of Generic Drugs (OGD), Office of Research and Standards, Division of Therapeutic Performance has made… Read more . . .
-
Generic DPI device developer Merxin has announced that its MRX003 capsule based dry powder inhaler has received CE marking certification. The inhaler, which was launched in May 2017, is designed for generic tiotropium products submitted… Read more . . .
-
Savara has submitted an investigational new drug application for Molgradex inhaled recombinant human GM-CSF for the treatment of autoimmune pulmonary alveolar proteinosis (PAP) to the FDA, the company said. In May 2017, the company said… Read more . . .
-
A citizen petition filed by Mylan on December 5, 2017 asks the FDA not to approve any ANDA for a generic version of Advair Diskus that relies on data from multiple-batch PK bioequivalence studies “unless,… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK